Briefing Information for the October 24, 2013 Meeting of the ADA Committee - Simeprevir

Persons with disabilities having problems accessing the PDF file(s) below may call (301) 796-3634 for assistance

FDA

Disclaimer: Portions of this document have been determined to be exempt from disclosure under the Freedom of Information Act (the FOIA) (5 U.S.C. § 552).

• FDA Briefing Information for the October 24, 2013 Meeting of the Antiviral Drugs Advisory Committee (PDF - 425KB)¹

Janssen Pharmaceutical Co.

Disclaimer: The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

• Janssen Briefing Information for the October 24, 2013 Meeting of the Antiviral Drugs Advisory Committee (PDF - 1.2MB)²
• Errata to the Janssen Briefing Information for the October 24, 2013 Meeting of the Antiviral Drugs Advisory Committee (PDF - 133KB)³ 

Page Last Updated: 10/22/2013
Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.

Source – FDA